Don't Bite The Hand That Feeds You

[sonny-888]

in VICL pre market 4.75
Vical Leaping Higher in Early Pre-Bell Trade on Preclinical Results with Vaxfectin Cancer Vaccine 09/24 07:09 AM

07:09 AM Eastern Daylight Time, 09/24/2009 (MidnightTrader) -- Vical (VICL:$4.22,00$-0.24,00-5.38%) announced the presentation of encouraging results from animal studies of a peptide-based cancer vaccine formulated with the company's Vaxfectin adjuvant.

Sean M. Sullivan, Ph.D., Vical's (VICL:$4.22,00$-0.24,00-5.38%) Executive Director of Pharmaceutical Sciences, is presenting data at the IIRUSA Vaccines Development Forum demonstrating the adjuvant's ability to enhance immune responses of cancer antigen-based vaccines in addition to a broad variety of DNA- and protein-based vaccines against infectious diseases.

The company noted that the latest data showed that mice vaccinated with a Vaxfectin-formulated TRP-2 melanoma tumor antigen peptide achieved significant improvements in cellular immune responses, reduced numbers of tumors, and a survival advantage compared with mice receiving control or no treatment.